Login
Home
Charts
Search
Watchlist
Products

Senores Pharmaceuticals Ltd

SENORES·NSE
₹1,379.90-1.09%Tue, 22 Sept '26
Industry:Pharma - API
Indices:

Senores Pharmaceuticals Ltd

SENORES
NSE
₹1,379.90
-1.09%
|Tue, 22 Sept '26
SOICxStockScans Reports
Industry
Pharma - API
Indices
View
Financials
Documents
Shareholdings
Corporate Actions
Segments
Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Peer Comparison
Financials
Documents
Shareholdings
Corporate Actions
Segments
Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Peer Comparison
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
₹6,355Cr
Close
Close Price
₹1,379.90
Industry
Industry
Pharma - API
PE
Price To Earnings
48.59
PS
Price To Sales
9.24
Revenue
Revenue
₹688Cr
Rev Gr TTM
Revenue Growth TTM
50.95%
PAT Gr TTM
PAT Growth TTM
90.56%

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
7910280101103114138162171175180
Growth YoY
Revenue Growth YoY%
30.911.571.760.865.953.430.6
Expenses
ExpensesCr
648059777795104112121128126
Operating Profit
Operating ProfitCr
1522212326193450504754
OPM
OPM%
19.321.926.523.124.917.024.830.629.527.129.8
Other Income
Other IncomeCr
1202512957183
Interest Expense
Interest ExpenseCr
23556556587
Depreciation
DepreciationCr
344445688910
PBT
PBTCr
1018131620212641454739
Tax
TaxCr
33334351111119
PAT
PATCr
714111316182130343730
Growth YoY
PAT Growth YoY%
131.126.794.1130.4104.4104.143.8
NPM
NPM%
9.013.813.613.015.915.715.318.619.620.916.9
EPS
EPS₹
4.08.03.43.95.03.84.66.57.38.06.6
QuarterDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
7910280101103114138162171175180
Growth YoY
Revenue Growth YoY%
30.911.571.760.865.953.430.6
Expenses
ExpensesCr
648059777795104112121128126
Operating Profit
Operating ProfitCr
1522212326193450504754
OPM
OPM%
19.321.926.523.124.917.024.830.629.527.129.8
Other Income
Other IncomeCr
1202512957183
Interest Expense
Interest ExpenseCr
23556556587
Depreciation
DepreciationCr
344445688910
PBT
PBTCr
1018131620212641454739
Tax
TaxCr
33334351111119
PAT
PATCr
714111316182130343730
Growth YoY
PAT Growth YoY%
131.126.794.1130.4104.4104.143.8
NPM
NPM%
9.013.813.613.015.915.715.318.619.620.916.9
EPS
EPS₹
4.08.03.43.95.03.84.66.57.38.06.6

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
1435215398633688
Growth
Revenue Growth%
149.4507.185.758.951.0
Expenses
ExpensesCr
1223173309464487
Operating Profit
Operating ProfitCr
2134290168201
OPM
OPM%
13.835.919.422.526.629.2
Other Income
Other IncomeCr
043194733
Interest Expense
Interest ExpenseCr
129222527
Depreciation
DepreciationCr
1210173135
PBT
PBTCr
1122571159172
Tax
TaxCr
04-8123841
PAT
PATCr
183358122131
Growth
PAT Growth%
751.0287.978.4108.390.6
NPM
NPM%
7.023.915.314.719.219.0
EPS
EPS₹
1.88.913.716.126.428.4
Financial YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
1435215398633688
Growth
Revenue Growth%
149.4507.185.758.951.0
Expenses
ExpensesCr
1223173309464487
Operating Profit
Operating ProfitCr
2134290168201
OPM
OPM%
13.835.919.422.526.629.2
Other Income
Other IncomeCr
043194733
Interest Expense
Interest ExpenseCr
129222527
Depreciation
DepreciationCr
1210173135
PBT
PBTCr
1122571159172
Tax
TaxCr
04-8123841
PAT
PATCr
183358122131
Growth
PAT Growth%
751.0287.978.4108.390.6
NPM
NPM%
7.023.915.314.719.219.0
EPS
EPS₹
1.88.913.716.126.428.4

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
910314646
Reserves
ReservesCr
2836174740888
Current Liabilities
Current LiabilitiesCr
1052248241424
Non Current Liabilities
Non Current LiabilitiesCr
1334143174215
Total Liabilities
Total LiabilitiesCr
591316221,2271,604
Current Assets
Current AssetsCr
2751251722812
Non Current Assets
Non Current AssetsCr
3280371504791
Total Assets
Total AssetsCr
591316221,2271,604
Financial YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
910314646
Reserves
ReservesCr
2836174740888
Current Liabilities
Current LiabilitiesCr
1052248241424
Non Current Liabilities
Non Current LiabilitiesCr
1334143174215
Total Liabilities
Total LiabilitiesCr
591316221,2271,604
Current Assets
Current AssetsCr
2751251722812
Non Current Assets
Non Current AssetsCr
3280371504791
Total Assets
Total AssetsCr
591316221,2271,604

Cash Flow

Consolidated
Standalone
Financial YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
-10-1-26-4662
Investing Cash Flow
Investing Cash FlowCr
-24-48-54-429-121
Financing Cash Flow
Financing Cash FlowCr
364687573-1
Net Cash Flow
Net Cash FlowCr
2-3798-60
Free Cash Flow
Free Cash FlowCr
-21-48-78-203
CFO To PAT
CFO To PAT%
-1,054.2-12.8-78.6-78.751.1
CFO To EBITDA
CFO To EBITDA%
-535.2-8.5-61.8-51.236.9
Financial YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
-10-1-26-4662
Investing Cash Flow
Investing Cash FlowCr
-24-48-54-429-121
Financing Cash Flow
Financing Cash FlowCr
364687573-1
Net Cash Flow
Net Cash FlowCr
2-3798-60
Free Cash Flow
Free Cash FlowCr
-21-48-78-203
CFO To PAT
CFO To PAT%
-1,054.2-12.8-78.6-78.751.1
CFO To EBITDA
CFO To EBITDA%
-535.2-8.5-61.8-51.236.9

Ratios

Consolidated
Standalone
Financial YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
2,6383,4906,355
Price To Earnings
Price To Earnings
45.030.348.6
Price To Sales
Price To Sales
6.65.59.2
Price To Book
Price To Book
3.43.76.8
EV To EBITDA
EV To EBITDA
28.621.732.9
Profitability Ratios
Profitability Ratios
GPM
GPM%
43.063.744.046.0
OPM
OPM%
13.835.919.422.526.629.2
NPM
NPM%
7.023.915.314.719.219.0
ROCE
ROCE%
3.313.57.58.414.614.6
ROE
ROE%
2.718.516.07.413.013.0
ROA
ROA%
1.76.45.34.87.67.6
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
2,6383,4906,355
Price To Earnings
Price To Earnings
45.030.348.6
Price To Sales
Price To Sales
6.65.59.2
Price To Book
Price To Book
3.43.76.8
EV To EBITDA
EV To EBITDA
28.621.732.9
Profitability Ratios
Profitability Ratios
GPM
GPM%
43.063.744.046.0
OPM
OPM%
13.835.919.422.526.629.2
NPM
NPM%
7.023.915.314.719.219.0
ROCE
ROCE%
3.313.57.58.414.614.6
ROE
ROE%
2.718.516.07.413.013.0
ROA
ROA%
1.76.45.34.87.67.6
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios

Documents — Senores Pharmaceuticals Ltd

  • Q1 FY2027 Earnings Call Transcript (Jun 2026, PDF): https://www.stockscans.in/document/oqh7q1104061zqu5dgm4esoz.pdf
  • Q4 FY2026 Earnings Call Transcript (Mar 2026, PDF): https://www.stockscans.in/document/nzq7djoxc6xtw6wu33brlv6c.pdf
  • Q3 FY2026 Earnings Call Transcript (Dec 2025, PDF): https://www.stockscans.in/document/89rdwdpin63im0f84dbht7cl.pdf
  • Q2 FY2026 Earnings Call Transcript (Sep 2025, PDF): https://www.stockscans.in/document/xjmekxyi68km850bon4fi3ve.pdf
  • Q1 FY2026 Earnings Call Transcript (Jun 2025, PDF): https://www.stockscans.in/document/2tujmlh0f301o0ze1kfiaxro.pdf
  • Q4 FY2025 Earnings Call Transcript (Mar 2025, PDF): https://www.stockscans.in/document/bqms29j27p765vyhbts75uu0.pdf
  • Q3 FY2025 Earnings Call Transcript (Dec 2024, PDF): https://www.stockscans.in/document/sg5ifezvf2cc0u05ts3t0hqk.pdf
  • Q1 FY2027 Quarterly Result (Jun 2026, PDF): https://www.stockscans.in/document/f8spiib4hx6ea6ode62auwwi.pdf
  • Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/21hx66b0qpgk3x2q3yv2r5ic.pdf
  • Q3 FY2026 Quarterly Result (Dec 2025, PDF): https://www.stockscans.in/document/7v1nn3y2tm2q2hz22o5d3clz.pdf
  • Q2 FY2026 Quarterly Result (Sep 2025, PDF): https://www.stockscans.in/document/1miyggdposis6039s966dqta.pdf
  • Q1 FY2026 Quarterly Result (Jun 2025, PDF): https://www.stockscans.in/document/pffqh6uvqlc2jyijk9li2bxq.pdf
  • Q4 FY2025 Quarterly Result (Mar 2025, PDF): https://www.stockscans.in/document/j9ajoccblyt4tc0ev98ytri9.pdf
  • Q3 FY2025 Quarterly Result (Dec 2024, PDF): https://www.stockscans.in/document/nalhkdxqp0xqycy025v5uvpi.pdf
  • Q1 FY2027 Investor Presentation (Jun 2026, PDF): https://www.stockscans.in/document/6rfyl20rn9irgggywq1tkcl1.pdf
  • Q4 FY2026 Investor Presentation (Mar 2026, PDF): https://www.stockscans.in/document/5fv87tgpb0hc3dql7efzuaz0.pdf
  • Q3 FY2026 Investor Presentation (Dec 2025, PDF): https://www.stockscans.in/document/pz0xiq3m4zn8wbsmp1ncdxfw.pdf
  • Q2 FY2026 Investor Presentation (Sep 2025, PDF): https://www.stockscans.in/document/xkdj8q7vvc9j66aanohvhd2n.pdf
  • Q1 FY2026 Investor Presentation (Jun 2025, PDF): https://www.stockscans.in/document/kyt9jyyobyhb7482ldhu5vbl.pdf
  • Q4 FY2025 Investor Presentation (Mar 2025, PDF): https://www.stockscans.in/document/04sppcrtirt58jmfcgf3imag.pdf
  • FY2026 Annual Report (PDF): https://www.stockscans.in/document/jd89l04mmcfhmdhgajdrb1qc.pdf
  • FY2025 Annual Report (PDF): https://www.stockscans.in/document/jt08v6f9spefjgdbtor79d3g.pdf

Concall Transcript Summaries — Senores Pharmaceuticals Ltd

  • Q1 FY2027 Concall Transcript Summary (Jun 2026): https://www.stockscans.in/company/NSE%3ASENORES/transcript-notes/202606/oqh7q1104061zqu5dgm4esoz.pdf
  • Q4 FY2026 Concall Transcript Summary (Mar 2026): https://www.stockscans.in/company/NSE%3ASENORES/transcript-notes/202603/nzq7djoxc6xtw6wu33brlv6c.pdf
  • Q3 FY2026 Concall Transcript Summary (Dec 2025): https://www.stockscans.in/company/NSE%3ASENORES/transcript-notes/202512/89rdwdpin63im0f84dbht7cl.pdf
  • Q2 FY2026 Concall Transcript Summary (Sep 2025): https://www.stockscans.in/company/NSE%3ASENORES/transcript-notes/202509/xjmekxyi68km850bon4fi3ve.pdf
  • Q1 FY2026 Concall Transcript Summary (Jun 2025): https://www.stockscans.in/company/NSE%3ASENORES/transcript-notes/202506/2tujmlh0f301o0ze1kfiaxro.pdf
  • Q4 FY2025 Concall Transcript Summary (Mar 2025): https://www.stockscans.in/company/NSE%3ASENORES/transcript-notes/202503/bqms29j27p765vyhbts75uu0.pdf
  • Q3 FY2025 Concall Transcript Summary (Dec 2024): https://www.stockscans.in/company/NSE%3ASENORES/transcript-notes/202412/sg5ifezvf2cc0u05ts3t0hqk.pdf

Simplify stock analysis with powerful tools and clear insights for confident, data-driven decisions.

support@stockscans.in
© StockScans by SOIC Technologies Pvt Ltd
349 A, Lodhi Road, Punjabi Bazar, New DelhiData provided by CMOTS Internet Technologies